Therapeutic HIV vaccines: Prior setbacks, current advances, and future prospects

Vaccine

Volumn 32, Issue 43, 2014, Pages 5540-5545

  Fisher, Authors Kevin ^a   Voronin, Yegor ^b   Jefferys, Richard ^c  

^a AVAC: Global Advocacy for HIV Prevention   (United States)

^b Global HIV Vaccine Enterprise   (United States)

^c Treatment Action Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; HUMAN; IMMUNOLOGY; STUDY DESIGN; VIROLOGY; ANIMAL; CD8+ T LYMPHOCYTE; DISEASE MODEL; HIV INFECTIONS; MEDICAL RESEARCH; METHODOLOGY; ORGANIZATION;

AIDS VACCINES; ANIMALS; BIOMEDICAL RESEARCH; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CONGRESSES AS TOPIC; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; RESEARCH DESIGN;

EID: 84908539215     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.066     Document Type: Conference Paper

References (58)

1. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987, 327:473-476.
2. McMichael A.J., Borrow P., Tomaras G.D., Goonetilleke N., Haynes B.F. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010, 10:11-23.
3. Shan L., Deng K., Shroff N.S., Durand C.M., Rabi S.A., et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:491-501.
4. Rhee E.G., Barouch D.H. Translational mini-review series on vaccines for HIV: harnessing innate immunity for HIV vaccine development. Clin Exp Immunol 2009, 157:174-180.
5. Ackerman M.E., Alter G. Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res 2013, 11:365-377.
6. Vieillard V., Dereuddre-Bosquet N., Mangeot-Mederle I., Le Grand R., Debre P. An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques. Vaccine 2012, 30:6883-6891.
7. Klein F., Mouquet H., Dosenovic P., Scheid J.F., Scharf L., et al. Antibodies in HIV-1 vaccine development and therapy. Science (New York, NY) 2013, 341:1199-1204.
8. Cadogan M., Austen B., Heeney J.L., Dalgleish A.G. HLA homology within the C5 domain promotes peptide binding by HIV type 1 gp120. AIDS Res Hum Retroviruses 2008, 24:845-855.
9. Kulpa D.A., Lawani M., Cooper A., Peretz Y., Ahlers J., et al. PD-1 coinhibitory signals: the link between pathogenesis and protection. Sem Immunol 2013, 25:219-227.
10. Lu W., Chen S., Lai C., Guo W., Fu L., et al. Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep 2012, 2:1736-1746.
11. Pantaleo G., Levy Y. Vaccine and immunotherapeutic interventions. Curr Opin HIV AIDS 2013, 8:236-242.
12. Vanham G., Van Gulck E. Can immunotherapy be useful as a "functional cure" for infection with human immunodeficiency virus-1?. Retrovirology 2012, 9:72.
13. Douek D.C., Betts M.R., Brenchley J.M., Hill B.J., Ambrozak D.R., et al. A novel approach to the analysis of specificity, clonality and frequency of HIV-specific T cell responses reveals a potential mechanism for control of viral escape. J Immunol (Baltimore, MD: 1950) 2002, 168:3099-3104.
14. Brenchley J.M., Douek D.C. HIV infection and the gastrointestinal immune system. Mucosal Immunol 2008, 1:23-30.
15. Douek D.C., Brenchley J.M., Betts M.R., Ambrozak D.R., Hill B.J., et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002, 417:95-98.
16. Estes J.D., Haase A.T., Schacker T.W. The role of collagen deposition in depleting CD4+ T cells and limiting reconstitution in HIV-1 and SIV infections through damage to the secondary lymphoid organ niche. Sem Immunol 2008, 20:181-186.
17. El-Far M., Halwani R., Said E., Trautmann L., Doroudchi M., et al. T-cell exhaustion in HIV infection. Curr HIV/AIDS Rep 2008, 5:13-19.
18. Appay V., Almeida J.R., Sauce D., Autran B., Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007, 42:432-437.
19. Saag M., Deeks S.G. How do HIV elite controllers do what they do?. Clin Infect Dis: Off Publ Infect Dis Soc Am 2010, 51:239-241.
20. Emu B., Sinclair E., Hatano H., Ferre A., Shacklett B., et al. HLA class I-restricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J Virol 2008, 82:5398-5407.
21. Tomescu C., Duh F.M., Hoh R., Viviani A., Harvill K., et al. Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS (London, England) 2012, 26:1869-1878.
22. Lambotte O., Pollara J., Boufassa F., Moog C., Venet A., et al. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One 2013, 8:e74855.
23. Lassen K.G., Lobritz M.A., Bailey J.R., Johnston S., Nguyen S., et al. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS Pathog 2009, 5:e1000377.
24. Abdel-Mohsen M., Raposo R.A., Deng X., Li M., Liegler T., et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology 2013, 10:106.
25. Yan J., Sabbaj S., Bansal A., Amatya N., Shacka J.J., et al. HIV-specific CD8+ T cells from elite controllers are primed for survival. J Virol 2013, 87:5170-5181.
26. Gulzar N., Copeland K.F. CD8+ T-cells: function and response to HIV infection. Curr HIV Res 2004, 2:23-37.
27. Karlsson I., Brandt L., Vinner L., Kromann I., Andreasen L.V., et al. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunol 2013, 146(2):120-130.
28. Barouch D.H., Whitney J.B., Moldt B., Klein F., Oliveira T.Y., Liu J., et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 2013, 503(7475):224-228. Epub 2013 Oct 30.
29. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., et al. Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther: J Am Soc Gene Ther 2013, 248. 10.1038/mt.2013.
30. Saez-Cirion A., Shin S.Y., Versmisse P., Barre-Sinoussi F., Pancino G. Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses. Nat Protoc 2010, 5:1033-1041.
31. Ho Y.C., Shan L., Hosmane N.N., Wang J., Laskey S.B., et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013, 155(3):540-551.
32. Laird G.M., Eisele E.E., Rabi S.A., Lai J., Chioma S., et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog 2013, 9:e1003398.
33. Rouzioux C., Richman D. How to best measure HIV reservoirs?. Opin HIV AIDS 2013, 8:170-175.
34. Persaud D., Luzuriaga K., Ziemniak C., Muresan P., Greenough T., et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (London, England) 2011, 25:2227-2234.
35. Howles S., Guimaraes-Walker A., Yang H., Hancock G., di Gleria K., et al. Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects. Vaccine 2010, 28:7306-7312.
36. Gandhi R.T., O'Neill D., Bosch R.J., Chan E.S., Bucy R.P., et al. A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine 2009, 27:6088-6094.
37. Garcia F., Routy J.P. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011, 29:6454-6463.
38. Garcia F., Climent N., Guardo A.C., Gil C., Leon A., et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013, 5(166):ra162.
39. Routy J.P., Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy 2010, 2:467-476.
40. Roederer M., Keele B.F., Schmidt S.D., Mason R.D., Welles H.C., et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 2013, 10.1038/nature12893.
41. Casazza J.P., Bowman K.A., Adzaku S., Smith E.C., Enama M.E., et al. Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire. J Infect Dis 2013, 207(12):1829-1840.
42. Persaud D., Luzuriaga K., Ziemniak C., Muresan P., Greenough T., et al. Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS 2011, 25(18):2227-2234.
43. Hansen S.G., Ford J.C., Lewis M.S., Ventura A.B., Hughes C.M., et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011, 473:523-527.
44. Hansen S.G., Piatak M., Ventura A.B., Hughes C.M., Gilbride R.M., et al. Immune clearance of highly pathogenic SIV infection. Nature 2013, 502:100-104.
45. Hansen S.G., Sacha J.B., Hughes C.M., Ford J.C., Burwitz B.J., et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (New York, NY) 2013, 340:1237874.
46. von Gegerfelt A., Valentin A., Alicea C., Van Rompay K.K., Marthas M.L., et al. Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus. J Immunol (Baltimore, MD: 1950) 2010, 185:3348-3358.
47. Valentin A., von Gegerfelt A., Rosati M., Miteloudis G., Alicea C., et al. Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine 2010, 28:1962-1974.
48. von Gegerfelt A.S., Rosati M., Alicea C., Valentin A., Roth P., et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 2007, 81:1972-1979.
49. Porichis F., Kaufmann D. Role of PD-1 in HIV pathogenesis and as target for therapy. Curr HIV/AIDS Rep 2012, 9(1):81-90.
50. Li J.Z., Brumme C.J., Lederman M.M., Brumme Z.L., Wang H., et al. Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial. PLoS One 2012, 7(3):e34134.
51. Saez-Cirion A., Bacchus C., Hocqueloux L., Avettand-Fenoel V., Girault I., et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog 2013, 9:e1003211.
52. Carcelain G., Autran B. Immune interventions in HIV infection. Immunol Rev 2013, 254:355-371.
53. The International AIDS Society Scientific Working Group on HIV Cure Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12:607-614.
54. Arts E., Biru T., Canaday D., Gao Y., Quinones-Mateur M., Nickel G. Using an autologous HIV vaccine/activator (based on the full length virus genome and the intrapatient virus population) to induce latent HIV and boost immunity. Global Antiviral J Abstr Book 2013, 9:1.
55. Yukl S.A., Boritz E., Busch M., Bentsen C., Chun T.W., et al. Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog 2013, 9:e1003347.
56. Chun T.W., Fauci A.S. HIV reservoirs: pathogenesis and obstacles to viral eradication and cure. AIDS (London, England) 2012, 26:1261-1268.
57. El-Sadr W.M., Lundgren J., Neaton J.D., Gordin F., Abrams D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006, 355:2283-2296.
58. UNAIDS Global report: UNAIDS report on the global AIDS epidemic 2013 2013, UNAIDS.